Clinical trials: Muscle Tumor
Leiomyomas
Diffusion -and Perfusion Weighted MRI for Response Prediction of Symptomatic Leiomyomas Following Uterine Artery Embolization
It is known that volumetric response of leiomyomas following uterine artery embolization correlates well with patients clinical outcome.
- Trial name
- NCT01514617
- Testing
- Diffusion -and perfusion weighted MRI including iv contrast agent injection
- Where
- Belgium
- Volunteers
- 100 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Rectal Cancer, Colorectal Cancer
Body Composition Manipulation in CoLorectal cancEr (BiCyCLE): Neuromuscular Electrical Stimulation (NMES)
Muscle is lost as part of the rectal cancer disease process. Surgery to treat rectal cancer and its subsequent immobility leads to increased muscle loss.
- Conditions
- Rectal Cancer, Colorectal Cancer, Colon Cancer, Colo-rectal Cancer
- Trial name
- BiCyCLE-NMES (NCT04065984)
- Testing
- Microstim 2v2 Stimulator
- Where
- United Kingdom
- Volunteers
- 46 people
- Sponsor
- London North West Healthcare NHS Trust
Bladder Cancer
Diagnostic Performance of the Vesical Imaging-Reporting and Data System (VI-RADS) in Detecting Muscle-invasive Bladder Tumour (MIBC) in Clinical Practice: Comparison With Transurethral Resection of Bladder Cancer (TURB) and Evaluation of Diagnostic Accuracy According to Tumour Location
VI-RADS was an observational, prospective, multicenter, no profit study. The aim of the study was to clarify the clinical validity of the Vesical Imaging-Reporting and Data System (VI-RADS) for the assessment of muscle invasion…
- Trial name
- VI-RADS (NCT06337591)
- Testing
- VI-RADS
- Where
- 3 sites in Italy
- Volunteers
- 20 people
- Sponsor
- Istituto Nazionale di Ricovero e Cura per Anziani
Uterine Fibroid, Myoma;Uterus
INTERVENTION WITH TRANEXAMIC ACID TO REDUCE HAEMORRHAGE DURING LAPAROSCOPIC MYOMECTOMY
This research is planned as a randomised double-blind controlled trial. interventions to reduce haemorrhage during laparoscopic myomectomy for fiboids is important.
- Conditions
- Uterine Fibroid, Myoma;Uterus, Tranexamic Acid Adverse Reaction
- Trial name
- NCT04192643
- Testing
- Tranexamic Acid 100 MG/ML
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Alkü Alanya Education and Research Hospital
Uterine Fibroid
Evaluating Efficacy of Intravenous Carbetocin Versus Intramyometrial Injection of Adrenaline in Reducing Blood Loss
Uterine fibroids, affecting 20-50% of all women ,and are benign tumors that arise from myometrial cells of the uterine smooth muscle tissue.
- Trial name
- NCT05986266
- Testing
- Carbetocin
- Where
- Egypt
- Volunteers
- 62 people
- Sponsor
- Egymedicalpedia
Lymphedema
Lymphedema Upper Limb of Breast Cancer Through Muscle Strengthening Associated With Complex Physical Therapy
The stage and lymphedema size can be detrimental to the quality of life and health of women, because the increase in circumference and member of the weight causes limitations in activities.
- Trial name
- LTP (NCT02574780)
- Testing
- complex physical therapy, Evaluate treatment of lymphedema, with in the quality of life and depression
- Where
- Brazil
- Volunteers
- 42 people
- Sponsor
- Federal University of São Paulo
Uterine Fibroids, Bleeding
A Clinical Study to Evaluate Safety of the ExAblate 2100 UF V2 System in the Treatment of Symptomatic Uterine Fibroids
The first magnetic resonance-guided focused ultrasound (MRgFUS) treatment of uterine fibroid using the ExAblate 2000 system was performed in 2001.
- Conditions
- Uterine Fibroids, Bleeding, Pain
- Trial name
- NCT01092988
- Testing
- Exablate 2100
- Where
- 4 sites in France, Israel and 2 more
- Volunteers
- 40 people
- Sponsor
- InSightec
Leiomyoma, Adenomyosis
Health-Related QoL Among Women Receiving Hysterectomy in NTUH
Laparoscopic assisted vaginal hysterectomy (LAVH)has become the most prevalent operation method in woman suffering from uterine myoma or adenomyosis nowadays.
- Trial name
- NCT00155870
- Testing
- questionnaires
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- National Taiwan University Hospital
Bladder Cancer, Bladder (Urothelial, Transitional Cell) Cancer Resectable (Pre-Cystectomy)
Feasibility of HISA During TURBT for NMIBC
The goal of this prospective pilot study is to evaluate the safety and feasibility of using heated saline during bladder tumor surgery in patients with non-muscle invasive bladder cancer.
- Conditions
- Bladder Cancer, Bladder (Urothelial, Transitional Cell) Cancer Resectable (Pre-Cystectomy), Non-muscle Invasive Bladder Cancer (NMIBC), Non-Muscle Invasive Bladder Neoplasms
- Trial name
- NCT07817173
- Testing
- HISA
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- CAMC Health System
Age-Related Macular Degeneration, Allergies
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and…
- Conditions
- Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease
- Trial name
- NCT05635266
- Testing
- Specimen sample
- Where
- United States
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Uterine Fibroids
Safety and Efficacy of Telapristone Acetate (Proellex®) Administered Vaginally for the Treatment of Uterine Fibroids
The primary objective of this study is to determine the safety and efficacy of two vaginal doses of Proellex® administered for up to 2 courses of treatment (18 weeks each), each separated by an Off-Drug Interval (ODI), to…
- Trial name
- NCT02323646
- Testing
- Telapristone Acetate
- Where
- 8 sites in United States
- Volunteers
- 42 people
- Sponsor
- Repros Therapeutics Inc.
Ewing's Sarcoma, Leukemia
Evaluation, Treatment, and Natural History of Children and Young Adults With Cancer or Rare Diseases
This protocol is designed to evaluate children with cancer who appear to be probable candidates for future protocol entry or have disease manifestations that are of unique scientific importance or educational value.
- Conditions
- Ewing's Sarcoma, Leukemia, Lymphoma, Brain Tumors
- Trial name
- NCT00001686
- Where
- United States
- Volunteers
- 482 people
- Sponsor
- National Cancer Institute (NCI)
Non Muscle Invasive Bladder Cancer
Efficacy of Gemcitabine Submucosal Injection for Preventing Recurrence in Intermediate- and High-Risk Non-Muscle-Invasive Bladder Cancer: A Randomized Trial
Bladder cancer is the most common malignant tumor of the urinary system in China, and its incidence has been increasing year by year.
- Trial name
- GEM-IR-NMIBC (NCT07198451)
- Testing
- Gemcitabine Submucosal Injection, Gemcitabine Intravesical Instillation
- Volunteers
- 320 people
- Sponsor
- Shanghai University of Traditional Chinese Medicine
Bladder Cancer, Muscle Invasive Bladder Cancer (MIBC)
Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy
Radical cystectomy is the standard of care for muscle invasive bladder cancer, however despite advances, it is still associated with high morbidity.
- Conditions
- Bladder Cancer, Muscle Invasive Bladder Cancer (MIBC), Muscle Invasive Bladder Cancer Urothelial Carcinoma, Cystectomy
- Trial name
- NCT07225205
- Testing
- Intravenous fluids, ERAS
- Where
- 2 sites in United States
- Volunteers
- 130 people
- Sponsor
- Johns Hopkins University
Dupuytren Disease
Ultrasound Features of Dupuytren's Disease
Dupuytren's disease (DD) is a benign and progressive condition that affects the palmar aponeurosis with a very high global incidence.
- Trial name
- Micro in DD (NCT06956027)
- Testing
- Ultrasound assesment, ROM measurement
- Where
- Belgium
- Volunteers
- 20 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Upper Tract Urothelial Carcinomas, Urothelial Bladder Cancer
Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations
This is a Phase 3 multicenter, double-blind, randomized, placebo-controlled study to evaluate the efficacy of infigratinib (an oral targeted FGFR1-3 inhibitor) versus placebo, as adjuvant treatment following surgery in adult…
- Trial name
- PROOF302 (NCT04197986)
- Testing
- Infigratinib
- Where
- 143 sites in United States, Belgium and 9 more
- Volunteers
- 39 people
- Sponsor
- QED Therapeutics, a BridgeBio company
High-Risk Non-Muscle-Invasive Bladder Cancer
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
This is a Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants with High-Risk Non-Muscle-Invasive Bladder Cancer.
- Trial name
- NCT06567743
- Testing
- Cretostimogene Grenadenorepvec
- Where
- 80 sites in United States, Canada
- Volunteers
- 325 people
- Sponsor
- CG Oncology, Inc.
Bladder Cancer Cell Transitional
Sarcopenia and NMIBC Prognosis Study
The goal of this observational study is to evaluate whether body composition abnormalities (sarcopenia, myosteatosis, and obesity) and nutritional status influence the risk of recurrence and progression in adult patients with…
- Trial name
- SARC-NMIBC (NCT07285408)
- Volunteers
- 150 people
- Sponsor
- General Hospital Sveti Duh
Urinary Bladder Neoplasms
A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC)
A study comparing nivolumab and bacterial drugs given to help the body's immune system in the bladder versus bacterial drugs alone in high risk bladder cancer participants.
- Trial name
- CheckMate 7G8 (NCT04149574)
- Testing
- nivolumab, Bacillus Calmette-Guérin (BCG)
- Where
- 63 sites in United States, Argentina and 14 more
- Volunteers
- 13 people
- Sponsor
- Bristol-Myers Squibb
Muscle-Invasive Bladder Carcinoma
Cisplatin, Nab-paclitaxel, Nivolumab With Radiotherapy After Resection of Non-Metastatic Muscle Invasive Bladder Cancer
In this phase II study, eligible patients will be treated with maximal tumor resection and then started treatment within 8 weeks. Chemotherapy, Nivolumab and radiotherapy (RT) will be started on day one.
- Trial name
- CNN-BC (NCT05203913)
- Testing
- Nivolumab, Nab paclitaxel, Cisplatin
- Where
- Italy
- Volunteers
- 32 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.